Year All2024202320222021202020192018201720152014 Aug 08, 2024 CG Oncology Reports Second Quarter 2024 Financial Results and Provides Business Updates Jun 18, 2024 CG Oncology Initiates Expanded Access Program for Cretostimogene Grenadenorepvec Jun 06, 2024 CG Oncology Announces Nature Medicine Publication of Final Results from CORE-001 Study of Cretostimogene Grenadenorepvec in Combination with Pembrolizumab in BCG-Unresponsive NMIBC May 24, 2024 CG Oncology to Present Positive Final Results from Phase 2 CORE-001 Study of Cretostimogene Grenadenorepvec in Combination with Pembrolizumab in BCG-Unresponsive High-Risk NMIBC at ASCO 2024 Annual Meeting May 09, 2024 CG Oncology Reports First Quarter 2024 Financial Results and Provides Business Updates May 03, 2024 Cretostimogene Monotherapy Demonstrated 75.2% Complete Response Rate in High-Risk, BCG-Unresponsive Non-Muscle Invasive Bladder Cancer Apr 26, 2024 CG Oncology to Host Virtual Investor Event on Friday, May 3, 2024 Apr 24, 2024 CG Oncology to Unveil Encouraging Results on Cretostimogene in Combination with Pembrolizumab at ASCO 2024 Mar 28, 2024 CG Oncology to Present Results on Cretostimogene at the AUA 2024 Annual Meeting Feb 27, 2024 CG Oncology Announces First Patient Dosed in PIVOT-006 Phase 3 Clinical Trial of Cretostimogene in Intermediate-risk Non-Muscle Invasive Bladder Cancer
Jun 06, 2024 CG Oncology Announces Nature Medicine Publication of Final Results from CORE-001 Study of Cretostimogene Grenadenorepvec in Combination with Pembrolizumab in BCG-Unresponsive NMIBC
May 24, 2024 CG Oncology to Present Positive Final Results from Phase 2 CORE-001 Study of Cretostimogene Grenadenorepvec in Combination with Pembrolizumab in BCG-Unresponsive High-Risk NMIBC at ASCO 2024 Annual Meeting
May 03, 2024 Cretostimogene Monotherapy Demonstrated 75.2% Complete Response Rate in High-Risk, BCG-Unresponsive Non-Muscle Invasive Bladder Cancer
Apr 24, 2024 CG Oncology to Unveil Encouraging Results on Cretostimogene in Combination with Pembrolizumab at ASCO 2024
Feb 27, 2024 CG Oncology Announces First Patient Dosed in PIVOT-006 Phase 3 Clinical Trial of Cretostimogene in Intermediate-risk Non-Muscle Invasive Bladder Cancer